U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Former executives of the pharmaceutical giant are backing a push by activist investor Starboard Value to turn aro ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

A federal judge ordered the tech giant to let rival app stores onto its Android smartphone platform, adding to its growing ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...